Business
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico
COFEPRIS (Mexico’s equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE’s Sildenafil, Vitamin D3,
About this update from Currenc Group Inc.
[{"type":"text","content":"COFEPRIS (Mexico’s equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE’s Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE’s patented Oral Thin Film (OTF) dose form CUREform™\nOXNARD, Calif. and LAS VEGAS, March 03, 2022 (GLOBE NEWSWIRE) -- Cure Pharmaceutical (OTC: CURR) a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, and Milagro Pharmaceuticals, which seeks first mover advantage in target heath & wellness markets through key collaborations, today announced their collaboration to register and sell in Mexico a number of CURE’s OTC and medical compounds that utilize CUREform™, CURE’s patented drug delivery platform for oral thin film (OTF). Cure is in discussions with several large distributors in Mexico and Latin America. OTF products that will be marketed and sold in Mexico via key distribution partners, include: CUREfilm Blue™ - an oral soluble form of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED).Vitamin D3 - that provides a convenient, weekly 40,000 IU dose of Vitamin DAn electrolyte energy boost - that provides a healthier, sugar-free alternative to energy drinksSleep - a dose of melatonin that dissolves on the tongue so it can be taken even after you climb into bed. The opportunity to serve the Latin American market with this venture into Mexico is an exciting one that is expected to accelerate the ramp up of CURE’s FDA-registered, cGMP manufacturing facility, where the Company pioneered and developed its patented CUREfilm™, drug delivery platform. The Company expects to select a distribution partner for the the LATAM territory in the coming months. Martin Simon, CEO of Milagro Pharmaceuticals, stated, “We are pleased to be working with CURE to bring their innovative wellness products and proprietary drug forms and delivery systems to Mexico, with the intention to extend our collaboration to encompass the rest of Latin America where the demand for health & wellness products is growing more rapidly than many other parts of the world.” About CURE PharmaceuticalCURE is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicl...